- Chinese︱Feedback︱Save this page
Get RSS feed
Check out RSS, or use RSS reader to subscribe this item 
Confirmation
Authentication email has already been sent, please check your email box: and activate it as soon as possible.
You can login to My Profile and manage your email alerts.
If you haven’t received the email, please:
- Login︱Register
|
|
|
 |
|
||
| There are 41 papers published in subject: > since this site started. | |||
| Select Subject |
| Select/Unselect all | For Selected Papers |
Saved Papers
Please enter a name for this paper to be shown in your personalized Saved Papers list
|
 |
| 1. The role of miR-451 in the switch between proliferation and migration in malignant glioma cells depends essentially on AMPK signaling which thereby modulates mTOR and Rac1 activation | |||
| Zhao Kai,Wang Leilei,Li Tao,Zhu Meng,Zhang Chen,Chen Lei,Zhao Pengfei,Zhou Hua,Yu Shengping,Yang Xuejun | |||
| Clinical Medicine 10 January 2017 | |||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most common primary neoplasm of the central nervous system (CNS), which has the highest malignancy and mortality rates. It is the invasive nature of GBM still complicates surgical resection and restricts chemotherapeutic access contributing to gloomy outcomes. The migration of tumor cells is closely related to the tumors proliferation. The alteration of cell phenotype is proposed to be a crucial mechanism with some of intracellular factors during this invasive progession. Using qRT-PCR analysis, we found that the expression of miR-451 in glioma tissues was lower than control brain tissues, especially in central area. In glioma cell lines, we found that decreased miR-451 expression suppressed tumor cells proliferation but enhanced the migration with low level of mTOR activation and high level of Rac1 activation respectively. Interestingly, the effect of miR-451 on glioma cytological behaviors and activation of mTOR and Rac1 was narrowed when we knocked down the AMPKa1 expression with a synthetic shRNA. We suggest that the different micro niche of glioma result in the heterogeneity of miR-451 expression. Our data indicated that miR-451, through adjusting the activity of AMPK, the hub regulator in the downstream pathway, reconfigures the activation of mTOR and Rac1, which play key roles on proliferation and migration respectively in glioma cells adapting to environment condition in the tumor. Whether a therapeutic target would promote cell infiltration has to be considered when we focus on the suppression of tumor cells proliferation. | |||
| TO cite this article:Zhao Kai,Wang Leilei,Li Tao, et al. The role of miR-451 in the switch between proliferation and migration in malignant glioma cells depends essentially on AMPK signaling which thereby modulates mTOR and Rac1 activation[OL].[10 January 2017] http://en.paper.edu.cn/en_releasepaper/content/4717205 | |||
| 2. Recent Advances of MicroRNAs in Castration-Resistant Prostate Cancer | |||
| ZHU Jin,SHAN Yuxi | |||
| Clinical Medicine 21 October 2016 | |||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:MicroRNAs (miRNAs) are a class of small non-coding RNAs with 18-26 nucleotides in length, which play important regulatory roles via binding to specific sites of mRNA of target genes and affect the cleavage of mRNA or the translation of protein. Castration-resistant prostate cancer (CRPC) is the advanced stage of prostate cancer (PCa), which is refractory to classic androgen deprivation therapy and other therapeutics. Recent studies found that miRNAs may play important roles in the initiation and progression of PCa, as well as the transformation of CRPC. This review mainly focuses on the methods of detecting key miRNAs in CRPC, as well as the roles of miRNAs in CRPC. | |||
| TO cite this article:ZHU Jin,SHAN Yuxi. Recent Advances of MicroRNAs in Castration-Resistant Prostate Cancer[OL].[21 October 2016] http://en.paper.edu.cn/en_releasepaper/content/4707172 | |||
| 3. Comparison of Thulium Laser Enucleation and Plasmakinetic Resection of the Prostate in a Randomized Prospective Trial With 5-Year Follow-up | |||
| YANG Zhonghua,WANG Xinghuan | |||
| Clinical Medicine 20 May 2016 | |||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:Purpose To compare the clinical outcomes between thulium laser transurethral enucleation of the prostate (ThuLEP) and plasmakinetic bipolar resection of the prostate (PKRP) for treating benign prostatic hyperplasia (BPH) in a prospective randomized trial with 5 years of follow-up. Materials and methods 158 consecutive patients with BPH were randomized to either ThuLEP (n = 79) or PKRP (n = 79). All cases were evaluated preoperatively and part of these patients were evaluated at 3-5 years postoperatively by International Prostate Symptom Score (IPSS), quality of life score (QoL), maximum ?ow rate (Qmax) and postvoid residual urine volume (PVR). Results A total of 80 patients completed the 5-year follow-up. Each study arm showed no significant difference in preoperative parameters. Compared with PKRP, ThuLEP required longer operation time (65.4 vs 47.4 minutes, p = 0.022) but resulted in less haemoglobin decrease (0.15 vs 0.30 g/dL, p = 0.045). ThuLEP also needed less catheterization time (2.1 vs 3.5 days, p =0 .031), irrigated volume (12.4 vs 27.2 L, p = 0.022) and hospital stay (2.5 vs 4.6 days, p = 0.026). During the 60 months follow-up, both procedures demonstrated no significant difference in terms of Qmax, IPSS, PVR, and QoL. Conclusions Both ThuLEP and PKRP relieve lower urinary tract symptoms equally with high efficacy and safety. ThuLEP was statistically superior to PKRP in blood loss, catheterization time, irrigated volume and hospital stay, but inferior to PKRP in operation time. However, both procedures showed no significant difference in terms of Qmax, IPSS, PVR, and QoLS through the 60 months follow-up.) | |||
| TO cite this article:YANG Zhonghua,WANG Xinghuan. Comparison of Thulium Laser Enucleation and Plasmakinetic Resection of the Prostate in a Randomized Prospective Trial With 5-Year Follow-up[OL].[20 May 2016] http://en.paper.edu.cn/en_releasepaper/content/4692025 | |||
| 4. Can EC-MPS reduce gastrointestinal side effects in de novo renal transplant recipients? | |||
| LI Fei,WANG Dongping,ZHAO Qiang,PAUL M.Schroder,LU Yao,ZHENG Zhouying,GUO Zhiyong,HE Xiaoshun | |||
| Clinical Medicine 23 November 2015 | |||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:Mycophenolate mofetil (MMF) is one of the major immunosuppressants commonly used in transplant recipients. Enteric coated mycophenolate sodium (EC-MPS) is expected to have immunosuppressant effects equivalent to MMF while reducing gastrointestinal adverse events. Here we conducted a meta-analysis on the comparison of outcomes of de novo renal transplant recipients using MMF versus EC-MPS. There was no statistical significance between EC-MPS and MMF groups in the incidence of gastrointestinal adverse events at both 3 months (Z=0.40, P=0.69) and 12 months (Z=0.45, P=0.65)after grouping. No difference was found in the incidence of dose reduction or interruption due to gastrointestinal adverse events between the two groups (Z=1.46, P=0.14 and Z=1.37, P=0.17). Similarly, no statistical significance was documented in the comparison of drug discontinuation due to gastrointestinal adverse events between the two groups at 12 months after grouping (Z=0.44, P=0.66). The 12-month biopsy proven acute rejection rates were comparable (Z=1.21, P=0.22). In summary, the current evidence suggests that EC-MPS has similar efficacy to MMF as an immunosuppressant but does not reduce the incidence of gastrointestinal side effects. | |||
| TO cite this article:LI Fei,WANG Dongping,ZHAO Qiang, et al. Can EC-MPS reduce gastrointestinal side effects in de novo renal transplant recipients?[OL].[23 November 2015] http://en.paper.edu.cn/en_releasepaper/content/4664319 | |||
| 5. Failure of initial superselective renal arterial embolization in the treatment of renal hemorrhage after percutaneous nephrolithotomy: a respective analysis of risk factors | |||
| Mao Qiqi,Wang Chaojun,Chen Geming,Shen Bohua,Tan Fuqing,Xie Liping | |||
| Clinical Medicine 16 November 2015 | |||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract: Background: Superselective renal arterial embolization (SRAE) is a well-established method for the treatment of severe hemorrhage after percutaneous nephrolithotomy (PCNL). However, there remains a significant rate of failures requiring repeat SRAE or nephrectomy. The aim of the present study is to identify risk factors for initial treatment failure of SRAE in patients with renal hemorrhage after PCNL. Methods: We retrospectively analyzed the data of patients who had undergone SRAE for severe bleeding due to PCNL. Data on patients who experienced initial treatment failure requiring repeat embolization or open surgery were compared with those on patients those who did not using univariate and multivariate analyses. Patient age, sex, kidney side, hypertention, diabetes, tract size, tract dilation methods, number of bleeding sites, arteriovenous fistula and renal vascular aberration/tortuosity were studied as potential predictors. Results: A total of 98 patients required SRAE for bleeding control after PCNL. Renal arteriography revealed pseudoaneurysm in 65, arteriovenous fistula in 6, and a combination of both in 11. Eleven patients had free extravasation, with coexisting pseudoaneurysm in 8 of them. Vascular aberration/tortuosity were encountered in ten patients. Seventeen patients (17.3%) experienced initial treatment failure and underwent repeat SRAE. On multivariate analysis, significant predictors of initial treatment failure included percutaneous tract size, number of bleeding sites and vascular aberration/tortuosity. Conclusions: In conclusion, repeated SRAE is preferred for patients who have experienced initial treatment failure with recurrent hemorrhage following PCNL. Our findings suggested that large tract size, multiple bleeding sites, and renal vascular aberration/tortuosity were significantly associated with increased risk of initial treatment failure of SRAE. This can assist interventional radiologists in the planning and execution of SRAE in this setting. | |||
| TO cite this article:Mao Qiqi,Wang Chaojun,Chen Geming, et al. Failure of initial superselective renal arterial embolization in the treatment of renal hemorrhage after percutaneous nephrolithotomy: a respective analysis of risk factors[OL].[16 November 2015] http://en.paper.edu.cn/en_releasepaper/content/4661789 | |||
| 6. Increased expression of cortactin is associated with prostate cancer progression/invasiveness and metastasis | |||
| MA Pengde,SHENG Bin,YANG Kuo | |||
| Clinical Medicine 06 February 2015 | |||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:Metastasis is the major cause of prostate cancer deaths.Cortactin is a protein that has been shown to be critical for the cancer cell migration and invasion and play an important role in tumor metastasis. However, the clinical significance of cortactin in prostate cancer and the role of cortactin in the progression and metastasis of prostate cancer are still not clear. In this study, we examined the cortactin expression in benign prostate and different stages of prostate cancer tissues including 26 BPH, 82 untreated primary cancer, 58 NHT cancer, 20 CRPC, and 13 metastatic prostate cancer tissues, and analyzed its relationship with clinicopathological factors. The result showed that cortactin expression increased gradually in different stages of cancer progression and was associated with prostate cancer metastasis. Further functional analysis showed that knockdown of cortactin protein by siRNA led to a marked reduction in PC-3 cell invasive ability and extracellular matrix degradation. Our findings suggested that expression of cortactin is correlated with the progression of clinical prostate cancer to more aggressive stages and provided support for the role of cortactin in prostate cancer cell invasion. Cortactin may serve as a promising biomarker and therapeutic target for metastatic prostate cancer. | |||
| TO cite this article:MA Pengde,SHENG Bin,YANG Kuo. Increased expression of cortactin is associated with prostate cancer progression/invasiveness and metastasis[OL].[ 6 February 2015] http://en.paper.edu.cn/en_releasepaper/content/4630291 | |||
| 7. Study on the Correlation between Vascular Mimicry and Apoptosis，and its Functions in the Prostate Carcinoma Metastasis | |||
| Yang Kuo,Zhao Yaorui,Nabin SHRESTHA | |||
| Clinical Medicine 16 January 2015 | |||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:Objective: The purpose of this thesis was retrospective study of the relationship of Vasculogenic mimicry and bone metastasis in prostate cancer tissue, preliminary analysis of the cell apoptosis and its function in the formation of VM and its regulation mechanism. Methods: 120 radical prostatectomy tissues were collected from the Second Hospital of Tianjin medical university from January 1, 1995 to December 31, 2010. All tissues were double stained with Platelet-endothelial cell adhesionmolecule-1 by Immunohistochemistry and Periodic acid-sciff. Then VM structure in tumor tissue were microscopically analyzed, the structure characteristics of VM and its distribution roles in tumor tissue. According to the follow-up data, this paper analyzes whether the existence of VM has relationship with bone metastasis. On this basis, with immunohistochemical stain to analyze apoptosis related proteins Bcl-2 and Casepase-3 expression in tissue of with and without VM .This paper discusses the rules of apoptosis in the formation process of VM. Results: From immunohistochemical staining of CD31 and PAS special histochemical staining,observed 37 cases of VM circuled by tumor cells in the total 120 cases with the positive rate of 30.8%. Within which red blood cells can be seen. The boundary membrane of VM is PAS positive, which can be incontinuous or continuous. VM is different from the endothelial vascular, the formation of the VM tumor cell do not secret CD31.Some deep stained nucleus. pyknosis, and fragmentation of tumor cells can be observed around VM in some prostate cancer tissue, but around it did not see inflammatory response significantly. In VM-positive group, 78.4 % had bone metastasis and 13.3% in VM-negative group, the difference was statistically (χ2 =48.8,P=0.000). In VM-positive group and negative group have shown different levels of Bcl-2 and Casepase-3.There are 9 cases with positive expression of Bcl-2 in 37 cases of VM-positive,the positive rate was 24.3%. Whereas there are 23 cases with positive expression of Bcl-2 in 38 cases of VM-negative, the positive rate was 60.5%. The positive expression rate of Bcl-2 in VM-positive group was significantly lower than the VM-negative group, the difference was statistically significant (χ 2 = 10.044, P = 0.002). There are 27 cases with positive expression of Casepase-3. in 37 cases of VM-positive, the positive rate was 73.0%. Whereas there are 11 cases with positive expression of Casepase-3 in 38 cases of VM-negative, the positive rate was 28.9%. The positive expression rate of Casepase-3. In VM-positive group was significantly higher than the VM-negative group, the difference was statistically significant (χ 2=14.537, P = 0.000). Conclusion 1.Prostate cancer tissue carried with VM is more likely to metastasis to the bone. 2. Activation of cell apoptosis regulation pathways plays an important role in the formation process of VM. | |||
| TO cite this article:Yang Kuo,Zhao Yaorui,Nabin SHRESTHA. Study on the Correlation between Vascular Mimicry and Apoptosis，and its Functions in the Prostate Carcinoma Metastasis[OL].[16 January 2015] http://en.paper.edu.cn/en_releasepaper/content/4629180 | |||
| 8. Different Treatment to AAST Grade III Blunt Pancreatic Trauma According to Injured Site | |||
| Kong Wencheng | |||
Clinical Medicine 18 November 2014
|
|||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:To determin if simple drainage operation is optimal to American Association for the Surgery of Trauma (AAST) grade III pancreatic trauma. Methodology: A series of 23 AAST grade III patients of blunt pancreatic trauma was retrospectively reviewed. A standardized operation of simple drainage was performed. Morbidity was compared between neck injured group and body/tail injured group. Results: The late-stage reoperation rate for unresolved pancreatic fistula was significantly lower in neck injury group than in body/tail injury group. Conclusions: Different management should be adopted according to the injured site within grade III trauma. Simple drainage surgery should be extended from grade IV/V injury to include neck injury of grade III trauma and distal pancreatectomy can be restricted to body or tail injury. | |||
| TO cite this article:Kong Wencheng. Different Treatment to AAST Grade III Blunt Pancreatic Trauma According to Injured Site[OL].[18 November 2014] http://en.paper.edu.cn/en_releasepaper/content/4618882 | |||
| 9. Immunosuppressive Characteristics of Forkhead Box P3-engineered Mouse Mesenchymal Stem Cells in Vitro | |||
| Li Jiequn,Qi Haizhi,Chen Guangshun | |||
Clinical Medicine 23 October 2014
|
|||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:In this paper, we sought to determine whether or not MSCs transfected with Foxp3 (MSC-Foxp3) exhibited stronger immunosuppressive activity than MSC-expressing vector (MSC-Mock) alone, and, if yes, define the essential mechanisms for this to occur. Successful gene transfer of Foxp3 was confirmed by Western blot analyses and Foxp3-engineered MSCs possess both the phenotype and differentiation ability associated with MSCs. Foxp3 transduction significantly improved the immunosuppressive activity of MSCs and involved both soluble mediators and cell contact-dependent mechanisms. Foxp3 transduction significantly increased the distribution of cell surface molecule neuropilin-1(Nrp-1) and costimulatory molecule programmed death ligand 1(PD-L1) in MSCs. It also promoted the induction of CD4+CD25+Foxp3+ Tregs and the production of soluble immunomodulatory factors interleukin-10 (IL-10) and transforming growth factor β (TGF-β). The findings suggest that Foxp3-engineered MSC therapy could be a promising and attractive cell therapy approach for inducing immunosuppression or transplant tolerance.an) | |||
| TO cite this article:Li Jiequn,Qi Haizhi,Chen Guangshun. Immunosuppressive Characteristics of Forkhead Box P3-engineered Mouse Mesenchymal Stem Cells in Vitro[OL].[23 October 2014] http://en.paper.edu.cn/en_releasepaper/content/4614071 | |||
| 10. Effects of timing of surgery in partial ACL injuried knees: a retrospective study involving 38 patients | |||
| BIN Li,PENG Shen | |||
| Clinical Medicine 26 February 2014
|
|||
| Show/Hide Abstract | Cite this paper︱Full-text: PDF (0 B) | |||
| Abstract:The aim of this study is to explore the optimal timing for surgical intervention of the partial injuried anterior cruciate ligament (ACL). Thirty-eight patients were divided into early surgery Group (n = 17) and delayed surgery Group (n = 21) based on the interval between injury and surgery, less than or beyond 3 weeks after injury. The minimum follow-up time was 2 years. The outcome measures used were the IKDC (International Knee Documentation Committee) scoring systems, Lysholm knee scoring scale, Tegner activity rating, range of motion (ROM) and the kneelax arthrometer. The preoperative associated lesions and side-to-side difference assessed by kneelax arthrometer postoperatively were significantly lower in the early surgery group than those in the delayed surgery group. No significant difference was observed in term of ROM, Lysholm, Tegner and IKDC scores 2 years postoperatively. The findings of this study indicate that early surgical reconstruction of the partial ruptured ACL could not result in arthrofibrosis, but prevent secondary loosening of the intact bundles and further meniscal and chondral injury. | |||
| TO cite this article:BIN Li,PENG Shen. Effects of timing of surgery in partial ACL injuried knees: a retrospective study involving 38 patients[OL].[26 February 2014] http://en.paper.edu.cn/en_releasepaper/content/4586805 | |||
| Select/Unselect all | For Selected Papers |
Saved Papers
Please enter a name for this paper to be shown in your personalized Saved Papers list
|
|
 |
|
||||||||||||||
About Sciencepaper Online |
Privacy Policy |
Terms & Conditions |
Contact Us
Technology Partner - CERNET